Active substances
Aluminium hydroxide + Magnesium hydroxide
- SFDA 17
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| MAALOX SUSPENSION | 45,40 mg,mg | Oral suspension · Oral use | 1 Bottle | SAR 5.90 | Generic · OTC | sanofi-aventis | Valid |
| MOXAL PLUS Tablet | 400,100 mg,mg | Chewable tablet · Oral use | 30 Blister | SAR 7.15 | Generic · OTC | Gulf Pharmaceutical Industries (Julphar) | Valid |
| MOXAL SUSPENSION | 405,100 mg,mg | Oral suspension · Oral use | 1 Bottle | SAR 9.10 | NCE · OTC | Gulf Pharmaceutical Industries (Julphar) | Valid |
| MOXAL Tablet | 405,100 mg,mg | Chewable tablet · Oral use | 30 Blister | SAR 6.65 | NCE · OTC | Gulf Pharmaceutical Industries (Julphar) | Valid |
| OMACID CHEWABLE TABLETS | 200,200 mg,mg | Chewable tablet · Oral use | 20 Blister | SAR 2.95 | Generic · OTC | National Pharmaceutical Industries Co. (SAOG) | Valid |
| RIALOX | 45,40 mg,mg | Effervescent granules · Oral use | 1 Bottle | SAR 7.40 | Generic · OTC | RIYADH PHARMA | Valid |
| ACIDAL CHEWABLE TAB | 400,100 mg | Tablet · Oral use | 30 Blister | SAR 6.45 | Generic · OTC | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| ACIDAL SUSPENSION | 405, 100 mg | Oral suspension · Oral use | 1 Bottle | SAR 7.40 | Generic · OTC | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| EMIXAL CHEWABLE TABLETS | 200, 200 mg | Chewable tablet · Oral use | 50 Blister | SAR 6.25 | Generic · OTC | GLOBAL PHARMA | Withdrawn by regulatory authority · Not Marketed |
| HYDROGEL SUSPENSION | 225, 200 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 3.45 | Generic · OTC | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| MAGALOX CHEWABLE TAB | 250, 250 mg | Chewable tablet · Oral use | 40 Blister | SAR 12.05 | Generic · OTC | BOSNALIJEK PHARMACEUTICAL | Withdrawn by MAH · Not Marketed |
| MAGALOX SUSPENSION | 225, 127 mg/ml | Suspension · Oral use | 1 Bottle | SAR 5.20 | Generic · OTC | BOSNALIJEK PHARMACEUTICAL | Withdrawn by MAH · Not Marketed |
| MEDACID CHEWABLE TABLET | 200, 200 mg | Chewable tablet · Oral use | 30 Blister | SAR 4.55 | Generic · OTC | MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES | Withdrawn by MAH · Not Marketed |
| MEDACID SUSPENSION | 45, 40 mg/ml | Suspension · Oral use | 1 Bottle | SAR 6.20 | Generic · OTC | MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES | Withdrawn by MAH · Not Marketed |
| MOXAL SUSP SACHET | 400, 200 mg | Granules for oral suspension · Oral use | 1 Sachet | SAR 5.20 | Generic · OTC | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| NOVAGEL SUSPENSION | 365 , 300 mg/ml | Suspension · Oral use | 1 Bottle | SAR 4.60 | Generic · OTC | APM | Withdrawn by MAH · Not Marketed |
| RIALOX | 225,200 mg | Tablet · Oral use | 30 Blister | SAR 5.95 | Generic · OTC | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
DYSPEPSIA; TUBERCULOSIS-SUPPORTIVE CARE
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.